Qiagen NV (Qiagen NV) Inventory-to-Revenue

: 0.78 (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Qiagen NV's Average Total Inventories for the quarter that ended in Dec. 2023 was $399 Mil. Qiagen NV's Revenue for the three months ended in Dec. 2023 was $509 Mil. Qiagen NV's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.78.

Qiagen NV's Inventory-to-Revenue for the quarter that ended in Dec. 2023 declined from Sep. 2023 (0.83) to Sep. 2023 (0.78)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Qiagen NV's Days Inventory for the three months ended in Dec. 2023 was 188.49.

Inventory Turnover measures how fast the company turns over its inventory within a year. Qiagen NV's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.48.

Qiagen NV Inventory-to-Revenue Historical Data

The historical data trend for Qiagen NV's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

0.11

0.12

0.14

0.16

0.19

Qiagen NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventory-to-Revenue																0.68	0.76	0.78	0.83	0.78

Competitive Comparison

For the Diagnostics & Research subindustry, Qiagen NV's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qiagen NV Inventory-to-Revenue Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Inventory-to-Revenue falls into.

Qiagen NV Inventory-to-Revenue Calculation

Qiagen NV's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (357.96	+	398.385)	/	2 )	/	1965.311
=	378.1725					/	1965.311
=	0.19

Qiagen NV's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (Q: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Revenue (Q: Dec. 2023 )
=	( (399.207	+	398.385)	/	2 )	/	509.162
=	398.796					/	509.162
=	0.78

Qiagen NV (NYSE:QGEN) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Qiagen NV's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	398.796	/	193.062	*	365 / 4
	=	188.49

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Qiagen NV's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	193.062	/	398.796
	=	0.48

Qiagen NV Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Qiagen NV's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Qiagen NV (Qiagen NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

1QGEN:Italy QIAd:UK 0RLT:UK QIA:Germany QIA:Germany QIA:Germany QIA:Germany QGEN:Austria

Address

Hulsterweg 82, Venlo, LI, NLD, 5912 PL

Website

https://www.qiagen.com

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).

Executives